Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
about
Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and ValnemulinIn vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBOptimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulationCurrent management of bloodstream infections.Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis.Emergence and spread of antibiotic resistance following exposure to antibiotics.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics.Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model.Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely ill Sub-Saharan African Patient Population.Pharmacokinetics, milk penetration and PK/PD analysis by Monte Carlo simulation of marbofloxacin, after intravenous and intramuscular administration to lactating goats.
P2860
Q28468397-EA26CC7A-C928-4F51-8F65-28AF50FC5B94Q34591451-CD99876D-2AE6-4AFE-82CE-ECA468B05123Q35644095-6D8D86A2-FA87-46AE-9C7A-B712C83D19CFQ37768418-F42672EA-EA60-4184-B422-AA1A38308F58Q37774343-1E75B0AE-5ACB-4C5C-8513-E115DBF6442DQ37896674-2F011390-DFEB-4DA1-A5E8-EB6B935604C9Q38692072-F44DD2DE-E837-44A3-BC2B-80617A8D5C49Q39293585-353D1DFC-EC94-470F-89B2-D1F89AB60C67Q42111255-5920EB2B-1A50-4135-B831-1AA929D946ADQ42127654-54B2DB0E-41FB-4F07-BD31-F02115312B59Q43803237-909290F8-DC95-4D1B-AC46-7F94CA68E63BQ43988363-D14EBCA1-20EA-4A33-BC8D-9046ECCB2FABQ46545782-465F4580-A3F9-4F76-A59B-4A25EF3C7EB2Q47774319-EB502A65-DE72-4984-B4B1-60A993D2F8AA
P2860
Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacodynamic assessment bas ...... s of Streptococcus pneumoniae.
@en
type
label
Pharmacodynamic assessment bas ...... s of Streptococcus pneumoniae.
@en
prefLabel
Pharmacodynamic assessment bas ...... s of Streptococcus pneumoniae.
@en
P2093
P2860
P356
P1476
Pharmacodynamic assessment bas ...... s of Streptococcus pneumoniae.
@en
P2093
Giichi Sugimori
Tomoyuki Homma
Toshihiko Hori
Yoshinori Yamano
P2860
P304
P356
10.1128/AAC.01372-06
P407
P577
2007-07-30T00:00:00Z